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Abstract
Human Immunodeficiency Virus Type 1 (HIV-1), a single stranded RNA
retrovirus, affects over 30,000,000 people world-wide1. The virus works by infecting
and promoting destruction of CD4 immune cells. and thus, suppressing proper immune
functions2. Contrary to DNA viruses, the absence of extensive proofreading
mechanisms in RNA viruses makes HIV latency a major obstacle in the discovery of
long-term, effective treatments. Moreover, the importance of exploring novel
therapeutic targets and designing complimentary inhibitory molecules remains
steadfast in HIV research3
Recently, HIV-1 Integrase (IN) multimerization, the core enzyme used for
integration of the viral DNA into an invaded host chromosome, has been identified as
an unexploited therapeutic target. Moreover, a class of quinoline based allosteric
integrase inhibitors (ALLINs) have shown promising inhibitory effects, most notably
in the assembly of inactive viral particles 4. The exact mechanism of action of this class
of molecules, however, remains unclear due to the multimodal role of the drug. Herein,
we report potencies of six synthesized single point derivatives of 4-phenylquinoline
using an innovative in vitro assay capable of measuring the multimerization between
full length IN and constructed C-terminal domain (CTD) using Fluorescence Resonance
Energy Transfer (FRET) and antibody-conjugated fluorophores. The potencies of IN
multimerizing drugs were characterized by their EC50 values obtained from the drug
concentration vs FRET curve. Our results, complimentary to recent studies, support the
proposed mechanism of action of this class of ALLINs and highlight the antiviral
potential of improved quinoline-based molecule derivatives to further exploit HIV-1 IN
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multimerization as a therapeutic target

Key Words: HIV-1 Integrase Multimerization, Allosteric Integrase inhibitors, Human
Immunodeficiency Virus
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acquired immunodeficiency virus
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C-terminal domain
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Chapter I: Introduction

Human Immunodeficiency Virus (HIV) affects over 36 million people world-wide
characterized by the progressive degradation of the immune system. If left untreated, the
infection results in the late stage Acquired Immunodeficiency Syndrome (AIDS),
characterized by a severe depletion of CD4+ T-cells and an incapacitated immune system5.
Although effective treatments have been discovered to control the spread of the virus
within a patient, a potential cure has yet to be identified. The homodimer interface of HIV
type 1 (HIV-1) integrase (IN), the viral enzyme central to the integration stage of the HIV1 life cycle, has recently been identified as a viable therapeutic target6. Moreover, a novel
class of quinoline based compounds has exhibited promising inhibitory effects on IN in
vitro3,7–9. Due to the high dynamic state of IN, crystallizing and characterizing the fulllength IN protein has proven difficult. Additionally, the proposed multimodal action of this
class of IN inhibitors has suggested evaluation of previous experimental designs to account
for the distinct mechanisms of inhibition and for the active site characterization10. Our
assay was designed to quantify multimerization potencies of synthesized compounds. To
conduct the assay, separate preparations of full length IN and recombinant CTD of IN were
marked with Flag and Histidine tags, respectively. Complimentary fluorophore-conjugated
antibodies were added to each preparation and then incubated in serial dilutions of the
drugs to be assayed. The EC50 values were obtained from the homogeneous time-resolved
fluorescence resonance energy transfer (HTR-FRET) signal exhibited between donor and
acceptor fluorophores.

1

Chapter II: Literature Review

HIV-1 Life Cycle
The HIV-1 life cycle occurs through a series of dependent steps involving both host
and viral proteins to induce an infection. (Figure 1). Glycoproteins on the virion surface
bind to the abundant receptors and coreceptors of the CD4 immune cell, allowing for
subsequent fusion of the two membranes. The contents of the virion are then released into
the cell where the viral proteins reverse transcribes the viral RNA, catalyzing the formation
and nuclear transport of the pre-integration complex (PIC)5.
After HIV-1 Integrase inserts the viral DNA into the host chromosome, the cell
becomes permanently infected and host proteins continuously transcribe and translate the
incorporated genetic material into chains of HIV-1 proteins. The viral proteins then
assemble into an immature HIV-1 particle, bud through the host’s cell membrane, and
begin maturation via proteolysis of the HIV protein chain (Figure 1)11. Inhibitory drugs are
categorized according
to their mode of action
within the viral life
cycle.

Current

FDA

approved drugs include
entry inhibitors, fusion
inhibitors,

reverse

transcriptase inhibitors
Figure 1: HIV Life Cycle and Current Inhibitor Targets
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(NRTIs & NNRTIs),

integrase strand transfer inhibitors (INSTIs), and protease inhibitors (PI)12. Each of these
HIV-1 drugs involves the disruption of a single stage in the viral life cycle, effectively
preventing further viral replication. The lack of proofreading mechanisms in retroviruses,
however, allows for spontaneous mutations from host cell to host cell, and thus, HIV
rapidly becomes resistant to drug treatments. Introduction of Highly Active Antiretroviral
Therapy (HAART) in 1996 offered a breakthrough in HIV treatment, transforming the once
universally fatal infection to a manageable chronic illness. Opposed to single-drug or dualdrug therapies, HAART targets three or more stages of the HIV life cycle, reducing the
probability of mutation and eliciting a synergetic antiviral effect13. Optimal HAART
treatment utilizes either a protease inhibitor (PI) or a nucleoside reverse transcriptase
inhibitor (NRTI), in combination with two non-non-nucleoside reverse transcriptase
inhibitors (NNRTIs) through an orally bioavailable drug cocktail12. Despite the success of
HAART, mutations that allow for multi-drug resistance and cross resistance continues to
hinder treatment. Additionally, diversity in a patient’s body introduces the possibilities of
insufficient drug metabolism or unmanageable side effects. These limitations require
altering medication cocktail, but the narrow selection of HIV drugs continues to restrict
HAART’s long-term effectiveness.

LEDGF/p75 Integration Factor
Despite the discovery, the HIV-1 infection in 19835, the role of host cellular
proteins remains unclear, and only a few have been thoroughly studied and characterized.
Epithelium-derived growth factor (LEDGF), an Endogenous and ubiquitous transcriptional
coactivator, is one of those few and has recently been the center of attention for its
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association with multiple lentiviral INs including HIV-1 IN14. The LEDGF/p75 cofactor
contains a chromatin-binding domain at the N terminus and the integrase binding domain
(IBD) at the C-terminus. During nuclear transport of the pre-integration complex (PIC),
the LEDGF/p75 engages IN at a cleft formed between interacting CCDs, then directs the
PIC to an active transcription site of the host chromosome. Using the crystal structure of
LEDGF/p75, the indicated studies suggested that the cofactor acts to tether the HIV-1 PIC
to cellular chromatin and is essential for initiating viral integration and replication. In a
study by Christ et al. on IN binding, IBD was overexpressed in human cells, and the
fragment efficiently competed with the endogenous LEDGF/p75 cofactor, inhibiting HIV
replication and integration to nearly undetectable levels15. Complimentary to the
characterization of the integrase binding domain (IBD) and the chromatin tethering regions
of LEDGF/p75, studies have indicated that the cofactor increases IN stability and protects
IN from degradation14. From these relevant studies, it can be deduced that integration can
be performed solely by IN; LEDGF/p75 is necessary, however, for precise and consistent
binding at an active transcription site. The progression of LEDGF/p75 research has, thus,
introduced a number of potential therapeutic HIV targets, particularly where the LEDGF
IBD contacts the IN.

HIV-1 Integrase as a Therapeutic Target
The HIV-IN protein monomer is characterized by three distinct domains: The Nterminal domain (NTD), the catalytic core domain (CCD), and the C-terminal domain
(CTD). Although each domain is essential for IN to carry out its enzymatic functions, the
CCD contains primary active site residues of Asp-64, Asp-116, and Glu-152. Dimerization
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between two CCD is favored in its highly dynamic, inactive state. The presence of viral
DNA promotes the association between IN dimers at their CCDs, thereby forming a
functional tetramer to carry out its enzymatic functions16. IN catalyzes two reactions in
vivo; the 3’ processing of the viral DNA after the PIC to the nucleus, and the strand transfer
reaction of the 3’ vDNA into the host DNA. The resulting strand transfer complex (STC)
contains strand discontinuation and hemi-integrated, flanking vDNA, both of which are
repaired by the host’s DNA polymerase, 5’-Flap endonuclease and DNA ligase, to form
the stable provirus17. This stage of the HIV-1 lifecycle is irreversible, and the infected cell
becomes a permanent carrier of the virus.
Studies of the LEDGF/p75 IBD interaction with IN have offered valuable data in
identifying and characterizing HIV-1 IN active sites for therapeutic exploitation. The cocrystal structure of a functional IN protein accelerated identification of drug targets and
complimentary inhibitory molecules. Due to its dynamic oligomeric state, however,
difficulty in crystalizing the active form of IN has hindered the exploitation of IN
structure/activity relationships. Nevertheless, alternative routes of protein structure
identification have presented similar incentives to researchers; the reported co-crystal
structure of an IN CCD dimer complexed with the LEDGF/p75 IBD18 has been especially
useful in advancing HIV drug discovery. In a proof-of-concept study, Christ et al.
evaluated the available LEDGF/p75 CCD co-crystal structure as a potential antiviral target.
The relevant protein to protein contact residues were then used to design small molecule
inhibitors and test their effects on HIV-1 replication in an infected cell. Notably, the 2quinolin-3-yl acetic acid-based compounds exhibited the most potency in inhibiting viral
replication. In addition to reducing LEDGF/p75-mediated integration, the compounds were
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found to block 3’-processing of the viral DNA ends15. Continued design and discovery of
small molecules that interfere with the IN to LEDGF/p75 interaction (LEDGINs) have
exemplified the promising therapeutic target. This reported class of compounds led to a
deeper investigation of the specific mechanism of action. Knockdown of endogenous
LEDGF/p75 led to a significant increase in potencies of the molecules in-vivo, suggesting
competitive binding between the cofactor and the compound during the early stages of viral
replication19. Although first coined as LEDGINs, literature on this class of compound has
evolved to suggest a multimodal, cooperative effect during early and late stages of viral
replication. In addition to inhibiting LEDGF-IN interactions, this class of molecules were
shown to also inhibit LEDGF-independent IN 3’ processing and strand transfer reactions.
Therefore, 2-quinolin-3-yl acetic acid derivatives were, more fittingly, reclassified as
Allosteric Integrase Inhibitors (ALLINIs)10. ALLINIs have been shown to effectively
promote aberrant IN multimerization within newly produced virions, resulting in
immature, noninfectious viral particles. Conclusively, the overwhelming evidence of
ALLINIs’ multimodal effect suggests a synergetic repression of HIV-1 with primary
potencies occurring through IN multimerization during late stage viral replication, and
secondary potencies through competitive binding with LEDGF in early stage viral
replication.
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Small Molecule Inhibitors of HIV-1 IN
Currently, FDA approved drugs that target the integration stage of HIV-1
replication, as are IN strand transfer inhibitors (INSTIs), such as raltegravir and
elvitegravir. Recent investigations have presented novel small molecule inhibitors that bind
to a non-catalytic site of HIV-1 IN, in contrast to INSTIs. The class of tricyclic quinoline
heterocycles have received considerable attention due to their potencies in the multimodal,
cooperative effect by allosterically inhibiting IN catalytic activity in early stage replication
as well as by promoting aberrant multimerization of IN subunits during late stage
replication.
The

2,3,4-trisubstituted

aryl

quinolines have been shown to exhibit
inhibitory effects against HIV-1 IN. Fader
Figure 2: Structures of notable
ALLINIs.

et al. used SAR and hit-to-lead studies to
report strategic substitutions of the quinoline
scaffold for maximal inhibition of IN 3’
processing
those

activity,

propositions

and
were

especially useful in our
identification and selection
of the optimal quinoline
scaffold
Figure 3: Three-Dimensional depiction of ALLINI-1
bound within the allosteric, hydrophobic pocket of the
HIV-1 IN CCD dimer. Separate IN monomer subunits
are color-coded.
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multimodal

for

maximal

potency

of

ALLINIs. The crystalized

IN-CCD with a bound ALLINI has also proved useful in the design of small molecule
inhibitors through hinting at the mechanism in which high-order multimerization is
promoted. Analysis of the protein to drug interactions revealed hydrogen bonding of the
ALLINI carboxylic acid with the Glutamine and Histidine residues of the CCD and the
ALLINI methoxy group with the Thr-174 residue of the same subunit. These observations
indicate that the 2-methyl and 3-acetic acid moieties are crucial for the drug’s secure
attachment within the deep, hydrophobic LEDGF binding pocket. Inclusion of a tert-butyl
substitution at the 3-carbon position of the scaffold (ALLINI-2) exhibited even stronger
binding affinity and increased the multimerization potency of the inhibitor. Moreover,
hydrophobic interaction occurred between the quinoline ring and the CTD of another IN
subunit. These findings aided us in developing derivatives to the trisubstituted 4arylquinoline scaffold (Figure 2) and implementing a structure-activity relationship study
that examines properties of IN multimerization according to scaffold substitutions. From
these preliminary investigations, optimization and derivation of the quinoline scaffold for
IN multimerization was carried out.
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HTRF-based FRET Analysis
The Fluorescence Resonance Energy Transfer (FRET) phenomenon occurs when
electron excitation of the donor fluorophore transfers its excitation energy to a nearby
acceptor fluorophore. In accordance to the Förster theory, the resulting FRET signal (E)
varies as the inverse sixth power of the molecular distance between donor and acceptor
fluorophores. This allows for FRET to be used as a precise molecular ruler for the IN
multimerization

assay.

In

characterizing the potency of
different

compounds,

the

effective concentration of the
drug required to exhibit a
half-maximal

response

(EC50) could therefore be
used to compare and analyze
repeated

and

varied

experiments.
Figure 4: The Fluorescence Resonance Energy Transfer (FRET)
signal occurs after initial excitation of Donor Fluorophore (320
nm) during IN Multimerization Assay. Resulting emission ratios
of the donor (620 nm) and the acceptor (665 nm) are
proportional to the FRET signal.

According to the reported
crystal

structure

of

an

ALLINI bound to the IN-

CCD dimer interface (Figure 3), the drug binds to the LEDGF binding pocket and then
promotes multimerization through hydrophobic interactions between the protruding
quinoline ring and the CTD of another IN subunit. In characterizing and comparing the
extent of multimerization of the synthesized drug derivatives, a previously described
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homogeneous time-resolved fluorescence (HTRF)-based assay20 was altered to
accommodate our research design. Mixed in a binding buffer, full-length IN was tagged at
the N-terminus with the FLAG epitope (FLAG-IN) and recombinant CTD of IN was tagged
with the hexahistidine epitope (HIS-CTD). Incubation of the tagged protein fragments with
a series dilution of the drugs to-be-tested, followed by addition of fluorophore-conjugated
antibodies. Europium cryptate conjugated Anti-His6 antibody and the XL665 conjugated
anti-FLAG antibody enabled the indirect measurement of CCD to CTD proximities (Figure
4).
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Chapter III: Materials and Methods

Construction of recombinant HIS-tagged CTD and FLAG-tagged IN used in the
assay were prepared as previously described10 and provided by the Kessl lab group. The
compounds tested were synthesized under a collaborative effort with the Donahue lab and
Pigza lab of the University of Southern Mississippi’s College of Arts and Science.

HTR-FRET IN Multimerization Assay
(All chemicals and substrates were purchased from Sigma-Aldrich or Fisher and were
used as received unless otherwise indicated.)
A 4 mL Tris-HCl Buffer containing 3496 μL mQ-H2O, 100 μL Tris-HCL (1 M),
300 μL NaCl (2 M), 8 μL MgCl2 (1 M), 40 μL Tween-20 (10%), and 70 μL BSA (75 mg/
mL). An IN-mix solution (2 mL) was prepared by adding His tagged CTD-IN (3 μL, 20.48
M) and Flag tagged full length IN (3 μL, 20.48 μM) to 2 mL of the reaction buffer and
incubated for 30 minutes at room temperature. Two drugs were tested during each assay.
IN-Mix (67 μL) and 2 μL of each drug dilution was added to a labeled microcentrifuge
tube (0.5 mL) and incubated for 3.5 hours at room temperature. An antibody mix (1.0 mL)
was prepared by adding fluorophore-conjugated antibodies, 7.92 μL of anti-His6-XL665
and 5 μL of anti-FLAG EuCryptate (Cisbio, Inc., Bedford, MA), and KF (188.7 μL, 1 M)
to the reaction buffer (745 μL). To each microcentrifuge tube, the antibody mix (33 μL)
was added and the reactions were incubated for 2 hours at RT. In a 384 well plate, 20 μL
of each reaction was added and left to settle for 20 minutes. The FRET signal efficiency
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was measured for each reaction-well twice. The average of the two readings were used to
plotted and fit the dose-response curve as previously described in the previous section.
For analysis of the drug-induced IN multimerization assay, a Molecular Devices
M5 plate reader was used to record the HTR-FRET signal from the corresponding reactions
in the 384-well plate. As previously conducted10,20, the FRET efficiency signal was defined
as a ratio between emission 2 (665 mm) and emission 1 (620 nm) multiplied by 10 6. To
normalize the data, Origin Software (OriginLab, Inc.) was used to plot and fit the doseresponse curve for each compound using the modified Hill equation (Equation 1). From
the curve, kn indicated the EC50 value for each compound. The EC50 of each compound
was used as the comparable measure for multimerization potency.

𝑦=

𝑥𝑛
𝑘𝑛 + 𝑥𝑛

Equation 1: The Modified Hill equation for the dose response curve is expressed, where
(x) is the inhibitor concentration, (y) is the percentage of inhibition, (k) is the EC50, and
(n) is the Hill slope10,21.
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Chapter IV: Data and Results

Drug induced IN multimerization was quantified through FRET analysis between
the interacting fluorophore-conjugated antibodies, anti-His6-XL665 and anti-FLAG
EuCryptate. The dose-response curve (Figure 5) was obtained for each of the tested drugs.
The X-axis defines the concentration of the drug (μM) and the Y-axis defines the extent of
multimerization activity. The EC50
value (k) was exhibited at the midpoint of the fitted-dose response
curve and was characterized by the
corresponding drug concentration.
The concentration of drug
required for 50% effectivity in vitro
(EC50) was used to characterize the
Figure 5: The fitted dose-response curve for
antiviral multimerization activity of compound
3 is shown.

potency of each compound (Table
1). In comparing different drugs, a

lower EC50 value deemed a drug more potent in promoting multimerization between HIV1 IN subunits, while a higher EC50 deemed a drug less potent. Derivatives of tri-substituted
4-arlyquinolines and their obtained EC50 values are shown in Table 1, columns 1-3.
Column 4 presents data from the previously reported, full length IN assay on identical
compounds7. Column 5 compares the results of the full-length assay with our modified
assay.
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Figure 7: Meta-4-phenylquinoline

Figure 6: Para-4-phenylquinoline

Compound Substitution (R) IN - CTD Assay IN - IN Assay7 Ratio of EC50
EC50 (μM)

EC50 (μM)

(IN-CT : IN-IN)

1

Cl (Para)

0.86

0.10

8.60

2

F (Para)

0.92

0.49

1.88

3

CH3 (Para)

0.43

0.24

1.79

4

Cl (Meta)

6.87

3.79

1.81

5

F (Meta)

No Inhibition

2.11

-----------

6

CH3 (Meta)

1.62

0.95

1.71

Table 1: Compound EC50 results according to substitution (R) in the para- and metaposition of Figure 6 and Figure 7, respectively.
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Chapter V: Discussion and Conclusion

Based on the obtained multimerization data, potency of the assayed quinoline based
molecules were shown to vary significantly with slight variations in molecular structure.
Compounds 4 and 5 were shown to have the least effect on IN Multimerization while
compound 3 was the most potent (EC50 of 0.43 μM). Drugs with variations in the metaposition showed lower potency than the variations in the para position. Also, a variation
from chlorine to methyl in the para position significantly increased potency, indicating that
the position of derivatization is associated with hydrophobic interactions inside of the
binding pocket.
When comparing the obtained EC50 values to that of the published full length IN
assay7, the data indicated a parallel in compounds 2, 3, 4, 5, and 6 (Table 1). All obtained
EC50 values were greater than those of the full-length assay, indicating less potent
multimerization. Additionally, the ratio between EC50 values of corresponding drugs
exhibited a ratio of approximately 2:1 for compounds 2, 3, 4, 5, and 6. The observed
differences in multimerization, however, do not vindicate less potent inhibitors. Since our
assay used identical equipment, techniques, and compounds as the published full-length
assay, EC50 values could be reliably compared. Our assay differed in that only the CTD of
IN was used rather than a full-length IN, suggesting that the absence of the NTD and CCD
modulated the measured FRET signal, and thus, increased the calculated EC50. This
relationship supports our hypothesis that the full-length assay data was influenced by not
only the drug induced multimerization, but also the consequential aggregation of additional
CCD drug binding sites (Table 1).
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The results of our IN-CTD assay suggested additional features of the proposed
allosteric drug binding model within the CCD of IN10. Although there is strong evidence
for the drug binding site being contained within the CCD dimer4,8,20, the effects of the
adjacent CTD and the NTD domains on the CCD drug binding sites has not been firmly
established. Substituting the HIS-CTD with a histidine tagged NTD, and then with histidine
tagged CCD, would contribute to the deciphering of the HIV-1 IN protein structure/activity
relationship.
Further testing on quinoline-based drug derivatives would provide valuable insight
on the activity within the CCD binding site. The infinite number of possible substitutions
in these novel compounds gives a promising outlook on HIV-1 IN drug discovery. The
scope of possible compounds, however, also presents hindrance since the synthesis of this
class of molecules has been relatively unexplored in literature. Given the immense
substitution possibilities, grouping potential substitutions by their polarity and atom size
could contribute in guiding future studies. The discovery and optimization of IN inhibitors
may also benefit from high throughput screening to propel pharmaceutical advancements
in HIV treatment, similar to the study used to identify optimal arylquinoline inhibitor
scaffolds20. In continued building of the trisubstituted arylquinoline compound library,
further insight on optimal binding of quinoline based drugs and analysis of their
multimerization potencies can contribute to deciphering the interface of therapeutic drug
interactions. Furthermore, refined and optimized ALLINIs that are successful in clinical
trials could be included to the current HAART treatments of controlling an HIV-1
infection, which would reduce the possibility of multi-drug, HAART resistant HIV-1
mutants. Potent inhibitors would also add to the narrow selection of compounds in
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HAART, thereby reducing the chance of a patient being incompatible with all available
treatment drugs. Our contribution of multimerization potencies of the presented ALLINIs
clarifies that multimerization continues to be a viable and relatively unexploited therapeutic
target, and that IN inhibitors could allow for desirable clinical properties.
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